GSE250023 Impaired Innate and Adaptive Immune Responses to BNT162b2 SARS-CoV-2 Vaccination in Persons with Systemic Lupus Erythematosus [RNA-Seq]

Series Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensUnderstanding the immune responses to SARS-CoV-2 vaccination is critical to optimize vaccination strategies for individuals with autoimmune diseases, such as systemic lupus erythematosus (SLE). Here, we comprehensively analyzed innate and adaptive immune responses in 19 patients with SLE receiving a complete two-dose Pfizer-BioNTech mRNA vaccine (BNT162b2) regimen compared to a control cohort of 56 healthy control (HC) volunteers. Patients with SLE exhibited impaired neutralizing antibody production and antigen-specific CD4+ and CD8+ T-cell responses relative to HC. Interestingly, antibody responses were only altered in patients with SLE treated with immunosuppressive therapies, whereas impairment of antigen-specific CD4+ and CD8+ T cell numbers was independent of medication. Patients with SLE also displayed reduced levels of circulating CXC motif chemokine ligands, CXCL9, CXCL10, CXCL11, and interferon (IFN)- γ after secondary vaccination, as well as downregulation of gene expression pathways indicative of compromised innate immune responses. Single-cell RNA sequencing analysis revealed that patients with SLE show reduced levels of a vaccine-inducible monocyte population characterized by over-expression of IFN-response transcription factors. Thus, although two doses of BNT162b2 induced relatively robust immune responses in patients with SLE, our data demonstrate impairment of both innate...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research